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The primary role of the APOBEC3 family of enzymes is within the innate immune 
system, acting to limit the infectivity of retroviruses through the deamination of their 
DNA intermediates by converting DNA cytosines to uracils, leaving behind a series of 
characteristic mutational signatures. However, over the years since the initial 
discovery of this family of enzymes and their roles, a series of landmark papers have 
been published that reveal the presence of these same signatures in a wide variety 
of human cancers, with APOBEC ranking as the second most commonly seen 
endogenous mutational signature across all human cancers. This discovery prompted 
investigations into the underlying mechanisms behind this and into the member of 
the APOBEC family most likely to be causing these endogenous mutations and its 
possible interactions with common chemotherapeutics, however results remain 
unclear and contentious with various studies by high-level labs and authors 
disagreeing and debunking one another.  
 
This study aimed to investigate the effect that A3A may have on the pace of 
development of resistance to cis-platin in BFTC-905 bladder cancer cells. This was 
due to be completed by using single cell culture and transfection techniques to 
expand numbers of colonies of A3A KO BFTC-905 cells that were created by a 
previous MSc-R student using CRISPR-Cas9, followed by a series of MTT assays and 
drug-sensitisation protocols on these A3A KO cells compared to their BFTC-905 WT 




BFTC-905 cells and verify their A3A status using qPCR but were unable to perform 






A brief history of the APOBEC’s 
The most common type of endogenous mutational signature in humans is the 
spontaneous deamination of methyl-cytosine bases that lead to C-to-T mutations – 
associated with age (Alexandrov et al., 2013). After this, the cytosine deamination 
activity of the APOBEC-family of enzymes is the second largest endogenous mutation 
source across all human cancers (Alexandrov et al., 2013). Despite this large 
mutagenic potential, there are 7 variants of the APOBEC3 enzyme found in humans 
and non-human primates (APOBEC3A, 3B, 3C, 3D, 3F, 3G and 3H) with fewer present 
in lower mammals, suggesting that this gene cluster may have arisen from an 
advantageous amplification event (Jarmuz et al., 2002) (Figure 1). Since DNA 
mutators pose an obvious threat to organisms with DNA genomes, the presence of a 
Figure 1 - Diagram showing the evolution and distribution of the APOBEC family of 
enzymes across several current mammals above the most likely common ancestor and 




large number of variants of APOBEC3 enzymes suggests that they must also confer 
some evolutionary advantage which must outweigh the risk of not possessing these 
enzymes at all. 
 
There are 11 members of the APOBEC (Apolipoprotein B mRNA Editing Catalytic 
Polypeptide-like) protein family, and all share a conserved zinc-dependent 
deaminase sequence motif that sits at the core of a catalytic cytidine deaminase 
domain. Variations in the secondary surrounding structures dictate cellular 
localisation, substrate specificity and the general function of each member of the 
APOBEC family. Of the APOBEC3 members all have a single catalytic site, but 
APOBEC3A, C and H are single-domain enzymes and ABOBEC3B, D, F and G are all 
double domain enzymes. The catalytic domains of APOBEC3A and APOBEC3B (the 
main subject of this thesis) share 92% amino acid sequence identity, and the proteins 
as a whole weigh approximately 23kDa and 46kDa respectively. 
 
APOBEC3 enzymes play an important role in the innate immune system by inhibiting 
retroviruses through the deamination of retroviral DNA intermediates (Harris & 
Figure 2 - Schematic of the cytosine deamination reaction catalysed by APOBEC 




Liddament, 2004). The first fundamental hallmark of APOBEC enzymes is their 
deamination activity of DNA cytosines to uracils. This deamination takes place 
through a zinc-mediated hydrolytic mechanism where water is de-protonated by 
glutamic acid, and the resultant hydroxide ion attacks the 4-position of the cytosine 
base. This results in the replacement of the amine group with a carbonyl group which 
ultimately results in the conversion of a cytosine into a uracil (Figure 2). The second 
hallmark feature is their preference for the DNA sequence surrounding the cytosine 
on which they act. Activation-Induced cytosine Deaminase (AID) prefers the target 
cytosine to be preceded by a purine, APOBEC3G prefers it to be preceded by another 
cytosine, and APOBEC1 along with APOBEC3A, 3B, 3C, 3D, 3F and 3H all prefer it to 
be preceded by a thymine ((Harris & Dudley, 2015) and references within). Whilst 
APOBEC1 and AID have roles in relation to RNA editing and antibody diversification 
respectively, APOBEC3 enzymes have roles relating to restriction of a multitude of 
viruses as well as endogenous transposable elements. The first member of the 
APOBEC family to be linked to viral restriction was A3G, at the time referred to as 
'CEM15' after the CEM-SS cell line that was found to be permissive to HIV/ΔVif 
infections during this early work. 
 
Two classic studies began to reveal the existence of the anti-retroviral action of some 
'factor' within certain types of cells. They describe this action as "a previously 
unrecognised form of cellular resistance to viral infection" (Simon et al., 1998). Initial 




can support the replication of HIV-1 strains that were deficient in Vif, termed HIV-
1/ΔVif. Those that can support replication of HIV-1/ΔVif were termed 'permissive', 
and those that cannot support it 'non-permissive' (von Schwedler et al., 1993). 
Permissive cells produced ΔVif viruses that had infectivity levels indistinguishable 
from wild-type viruses, whilst the non-permissive cells produced ΔVif viruses that 
were 10-100X less infectious than the wild-type variant. This work lends itself to two 
possible explanations for this phenomenon; either permissive cells produce some 
activity or factor that can compensate for Vif, or non-permissive cells have some type 
of activity that can inhibit HIV-1 infectivity when in the absence of Vif. 
 
The first of the two classic studies to build on this idea and gain traction was that by 
Simon et al, 1998 (Simon et al., 1998). Their work revolved around attempting to 
experimentally prove one of these hypotheses by investigating the infectivity 
phenotype of HIV-1/ΔVif that had been produced by heterokaryons formed from 
permissive (CEM-SS, 293T) and non-permissive (HUT78) cells. Their work showed 
that these heterokaryotic cells retained the non-permissive phenotype with the 
produced virions being 10x less infectious when the host cells were infected with 
HIV-1/ΔVif compared to the wild type virus. This meant that there must have been 
some dominant activity present in the non-permissive cell lines that was not present 
in the permissive lines, and that at least one of the purposes of Vif was to counteract 





The second case study was published by Sheehy et al, 2002 (Sheehy et al., 2002), 
whose work built directly on that done by Simon et al. In order to identify possible 
genes that fit the criteria set out in this previous work, this study used a cDNA 
subtraction strategy on a pair of genetically related cell lines that exhibited different 
abilities in supporting HIV-1/ΔVif replication. These were the non-permissive CEM 
cell line, and the permissive CEM-SS cell line (a sub-clonal isolation of the CEM line). 
Subtracted cDNA's were then used as probes in northern analyses of RNA's extracted 
from a panel of permissive and non-permissive cells, revealing the presence of cDNA 
from a previously unknown gene that was termed CEM15. This gene was easily 
detected in the non-permissive cells in the panel, but only very minimally or not at 
all in the permissive cell lines (Figure 3). 
 
 
Figure 3 - Northern analysis of CEM15 expression non-permissive and permissive cell lines (Sheehy 





Further testing of the effects of CEM15 on HIV-1 virus particle production showed 
that compared to the wild type virus, which was mostly unaffected by CEM15 
expression, the ΔVif virus had extremely low levels of infection at any dose of CEM15 
tested in a 293T transiently transfected cell line. A database search of CEM15 at the 
time did reveal a record of a previously recognised gene, but with no known 
description or function. Further analysis of CEM15 showed certain portions that had 
high similarity to APOBEC-1, and the paper even reports the presence of a zinc-
binding domain (a critical component for the proper function of APOBEC enzymes) 
that it recognises has been previously identified in cytosine deaminases and states 
its importance in their catalytic activity. However, it did not explicitly state that CEM-
15 could be a member of the APOBEC family although this link was made by others 
in the years after this landmark paper was published. 
 
The huge reduction in the infectivity of HIV-1/ΔVif that was shown to exist when in 
the presence of this previously unknown factor revealed its enormous possible 
potential to contribute to the treatment of HIV-1 infections. These two studies paved 
the way for future research into how this factor works, and how it could be leveraged 
for real world use.  
 
Prior to this initial beneficial link between certain members of the family of APOBEC 




discovered (APOBEC-1) was accidently found to be a possible oncogene. One study 
was initially testing whether the overexpression of the newly found APOBEC-1 in the 
livers of transgenic mice and rabbits would cause a reduction in the expression of 
apo-B100 and LDL’s, both thought to be its primary target through mRNA cytidine 
deamination and creation of an early stop-codon, which would lead to a truncated 
version of apo-B100 (apo-B48) being formed (Yamanaka et al., 1995). Instead, they 
unexpectedly found that all of the transgenic mice and one of the transgenic rabbits 
had liver dysplasia and that many of the transgenic mice has hepatocellular 
carcinomas. The livers of the transgenic mice were all at least twice as large, and 
some more than ten times larger than their non-transgenic litter mates with one liver 
weighing 40% of the entire weight of the mouse it was harvested from. They found 
that these hepatic abnormalities depended specifically on the overexpression of the 
apo-B mRNA editing activity rather than any secondary side effects such as insertion 
effects of the transgene. In short, this study concluded that the significant oncogenic 
effects that they were seeing in the APOBEC-1 overexpressing, transgenic animals 
were due to aberrant mRNA editing by APOBEC-1 rather than DNA editing – an 
important difference. 
 
It was not until 2002 in Harris et al’s and Petersen-Mahrt et al’s papers (Harris et al., 
2002; Petersen-Mahrt et al., 2002) that it became clearer that members of the 
APOBEC family had the capability to act on and deaminate genomic DNA as well as 




phenotype of nucleotide transitions at dC/dG pairs (which are only found in DNA and 
not RNA) and also that the AID mutator phenotype is enhanced when there is a 
deficiency of uracil DNA glycosylase (which normally removes DNA uracils), further 





Fuel for cancer 
A chance to act on the human genome 
There is now a wealth of evidence from cancer genome sequencing studies 
implicating off-target APOBEC3 activity in generating mutations in cancer cells. 
APOBEC3's act only on ssDNA and not the dsDNA that makes up the human genome 
(Roberts & Gordenin, 2014). Whilst this specificity would in principle allow the 
APOBEC3's to act on and deaminate only viral ssDNA whilst not harming the dsDNA 
human genome, in reality this does not take into account the small but regular 
presence of human ssDNA when genomic dsDNA is replicating or undergoing 
transcription or repair. This leads to the possibility for the human genome becoming 
deaminated, which can in turn lead to mutations and ultimately the formation and 
accelerated evolution of a wide variety of cancers. 
 
Mutational signatures, Kataegis and a case for attention on A3A 
Cancer has long been known to occur as a result of mutations in proto-oncogenes 
and tumour suppression genes. Historically, not much was known about the types of 
signatures that could be the cause of the myriad of different cancers that exist, but 
more recent sequencing analysis has revealed a trail of ‘mutational signatures’ that 
consistently appear in a vast variety of different cancers, suggesting that the action 
of a relatively small number of substances can cause the wide variety of cancers seen 
in patients every day. These signatures have been characterised, with either just one 




pioneering study detailing such signatures found that whilst most signatures are 
unique to a small number of specific human cancer types, signatures 2 and 13 are 
found in a large variety of cancers and are attributable to the activity of the APOBEC 
family of cytidine deaminases (Alexandrov et al., 2013). 
 
Before these APOBEC signatures were ever first formally identified and catalogued 
(Alexandrov et al., 2013), they were seen in a multitude of cancers years earlier 
before the underlying mechanism was fully understood. For example, one of the TpC 
signatures that was later attributed to APOBEC activity was initially found on multiple 
protein kinase genes in breast cancer samples (Stephens et al., 2005), and also in lung 
and ovarian cancers (Greenman et al., 2007). Further whole genome analysis of 21 
breast cancers showed that this same TpC mutational signature was present across 
the whole genome of the samples, and also that this single mutational signature 
accounted for up to 90% of all detected mutations across the cancer genome for 
some patients (Nik-Zainal et al., 2012). Finally, these mutations were found in 
clusters and were highly strand co-ordinated, with many of the substitutions 
characterized by the same distinctive C>T transitions at TpC dinucleotides as was 
found in Stephens et al and Greenman et al (Nik-Zainal et al., 2012). A 'rainfall plot' 
was constructed, showing inter-mutational distance against mutation number. This 
revealed a general macro-mutational signature across much of the genome of one of 
the breast cancer samples with a central hyper-mutated micro-mutational signature, 




localised hypermutation was termed 'Kataegis' (Greek for "thunderstorm"), and the 
study concluded that the APOBEC family was likely responsible for this phenomenon 




Initially the general consensus among many different studies on the APOBEC 
enzymes placed a relatively equal level of blame for the cancer-causing members of 
the enzyme family on A3A and A3B. For example, Burns et al. 2013 analysed gene 
expression data and mutation patterns from over 4,800 exomes and 1,000,000 
somatic mutations and concluded that A3B was likely the cause of a large fraction of 
Figure 4 – A rainfall plot showing the macro and micro hyper-mutational signature patterns identified in a 
PD4107a breast cancer cell line with a BRCA1 germline mutation. Mutations are ordered on the x axis from 
the first variant on the short arm of chromosome 1 to the last variant on the long arm of chromosome X. The 
distance between each mutation and the one prior to it (the inter-mutation distance) is plotted on the vertical 




dispersed and clustered cytosine mutations in six different types of cancer, including 
bladder cancer (Burns, Temiz, et al., 2013). The seminal paper by Alexandrov et al 
2013 linked the presence of the APOBEC mutational signatures to the action of 
APOBEC1, A3A or A3B over any other member of the APOBEC family (Alexandrov et 
al., 2013), and Taylor et al, 2013 found that mutation data derived from yeast 
revealed that A3A and A3B were the only deaminases whose target specificity 
matches the mutational and kataegic patterns found in breast cancer, concluding 
that they are both very likely to be involved in breast cancer hypermutation. This was 
in agreement with another study by Burns et al 2013 (Burns, Lackey, et al., 2013) 
which came to the same conclusion. 
 
It wasn’t until 2015 that this consensus was challenged in a study by Chan et al. They 
definitively showed that the mutational signatures left behind by A3A and A3B, which 
were previously thought to be too similar to reliably distinguish from one another, 
were in fact statistically distinguishable. The study also found that in five different 
cancer types there were more than 11 times more A3A-like mutations than A3B-like 
mutations, and that BRCA breast cancer patients with a relatively common 
APOBEC3B germline deletion still had A3A mutational signatures present, as well as 
at levels higher than that of patients without the A3B deletion confirmed by Fisher’s 
exact tests (Chan et al., 2015). Taken together their results would suggest that, 
contrary to previous data, A3A is in fact the more predominant mutagenic deaminase 




Cortez et al’s paper which found that the A3B targeting shRNA that was used in Burns 
et al’s 2013 seminal study to claim that A3B activity is the main culprit behind cytidine 
deamination (Burns, Lackey, et al., 2013), actually also decreased endogenous A3A 
mRNA levels by up to 13.8-fold. This means that Burns et al’s study is fundamentally 
flawed, as there is no way of knowing from their data whether the 30-70% reduction 
in genomic uracil loads (APOBEC-induced mutations) was truly to do with the 
reduction in expression of A3B, or if it was actually down to a reduction in expression 
of A3A. By selectively depleting A3A and A3B with different shRNA’s, Cortez et al 
showed that the levels of APOBEC-induced mutations present in BRCA cell lines 
linearly correlates with A3A expression, but not with A3B expression. In fact, in the 
BT474 APOBEC-mutated cell line in which the A3B mRNA transcript levels were on 
average 243-fold higher than A3A mRNA transcript levels, knockdown of A3A 
expression eliminated cytidine deaminase activity whilst knockdown of A3B 
expression had no effect, clearly showing that A3A is the dominant cytidine 
deaminase in these BT474 cells. Similar results were seen in the CAMA-1 and MDA-
MB-453 cell lines, where their cytidine deaminase activity was almost entirely 
dependent on A3A expression (Cortez et al., 2019).  
 
Taken together, these recent papers give a solid argument for the focus of research 
to be turned towards A3A, rather than A3B. It remains contentious as to where 
endogenous A3A localises, with some studies claiming it remains in the cytoplasm 




localisation and so would have access to cellular DNA (Bogerd et al., 2006; Mussil et 
al., 2013). However more recent papers such as that from Chan et al 2015 and Cortez 
et al 2019 give solid evidence to suggest that not only does A3A have direct access 
to genomic DNA, but through their novel methodologies they have also shown that 
A3A is a significantly more potent cellular DNA deaminase than A3B. 
 
Cause and effect – mutation mechanism in detail 
Despite their potent innate anti-viral activity, studies such as Nik-Zainal et al and 
others are more clearly coming to show that APOBEC's can cause somatic mutations, 
likely contributing to cell mutagenesis and formation of cancers within certain types 
of tissues.  
 
If the immediate product of A3A deamination is uracils and DNA uridines base-pair 
like thymidines and template the insertion of adenosines, then it would follow that 
the uracil products of A3A action would amplify by PCR to result in C/G to T/A 
transition mutations. One study used 3D-PCR to detect uridine-containing DNA 
intermediates in HEK-293T cells transfected with a reporter plasmid and either A3A 
or A3AE72A (a catalytically inactive mutant of A3A) expression plasmids, whilst in the 
presence of UGI (a uracil DNA glycosylase inhibitor). The 3D-PCR technique is based 
on the principle that DNA with fewer interstrand hydrogen bonds (i.e. more A/T rich 
regions, which under normal conditions are on average scarce and scattered in the 




denaturation temperatures. The study also used UGI to inhibit the UNG2 DNA 
glycosylase which would normally function to repair genomic uracils. This allows for 
the detection of otherwise short-lived uridine-containing DNA intermediates. 
 
Their results show that at higher denaturation temperatures, PCR products were 
seen in both the A3A and A3AE72A expressing cells, but at lower temperatures PCR 
products were only seen in the A3A expressing cells, suggesting that A3A does edit 
transfected plasmid DNA, leaving behind uracil-containing DNA intermediates 
(Stenglein et al., 2010). 
 
Other studies have reported increased presence of DNA damage response signalling 
in response to upregulated A3A expression in various cell lines. Increased A3A 
expression resulted in an increase in ɣH2AX (indicative of DSB’s being present) and 
ATR (indicative of a high level of ssDNA being present and protects against DNA 
replication stress) in Human U2OS and HepaRG cell lines (Green et al., 2016; Landry 
et al., 2011), with another study showing inhibition of ATR leading to replication 





Accelerating mutation formation 
More recently, there is strengthening evidence and support for the 'just right' 
hypothesis for tumour diversity (Swanton et al., 2015). This states that if there is too 
little diversity the tumour will fail to respond and adapt to selection pressures, and 
too much diversity will lead to genomic instability and cell lethality. Therefore, a 'just 
right sweet spot' of diversity may exist, where there is just enough genetic diversity 
to overcome the selection pressures that the tumours face, such as cancer treatment 
drugs, whilst not diverging so much 
that they fail to properly propagate 
genetic information to their daughter 
cells (Figure 5). Cancer cells may also 
have to attenuate APOBEC 
mutagenesis and enhance DNA repair 
mechanisms to ensure cell survival 
(Venkatesan et al., 2018). Given the 
mutation rates that APOBEC enzymes 
can cause, it is plausible that they may 
be able to foster this 'just right' level 
of diversity within tumour cell 
populations given the right 
circumstances. For example, one 
study looked at 100 surgically 
Figure 5 – Diagram illustrating how as APOBEC mutagenesis 
increases, the chance of lethal levels of mutagenesis within 
the cell populations also increases. However, a trade-off 
between lethal mutagenesis and cell population variation can 
create a optimal range where APOBEC mutagenesis can 





resected and untreated small-cell lung cancers and found a strong correlation 
between frequencies of APOBEC mutational signatures and overall numbers of sub-
clonal mutations (Jamal-Hanjani et al., 2017), and another study found that this kind 
of increased intra-tumour heterogeneity was shown to correlate with a shorter 
progression-free survival in some cancers (Andor et al., 2016). 
 
The formation of a ‘just right’ state for cancer cells with an APOBEC3 mutational load 
is unlikely to result solely from the presence of APOBEC3-induced mutations – 
APOBEC3’s require the presence of an ssDNA substrate which under most conditions 
is only present in very low quantities in any human cell. Rather, it’s more likely that 
a number of different circumstances come together in such a way that can promote 
the long-term survival of these tumours.  
 
Take urothelial carcinomas, which most often originate in the bladder (Mayo Clinic, 
n.d.). Bladder cancers are amongst the most mutated types of cancer overall 
(Lawrence et al., 2013), are associated with high morbidity and mortality rates 
(Kamat et al., 2016) and show the second highest levels of APOBEC-induced 
mutations of any cancer, only behind cervical cancer (Roberts et al., 2013). They are 
currently and commonly treated with cisplatin (Figure 6) or a combination of cisplatin 
with other chemotherapies (e.g. gemcitabine) or invasive procedures (e.g. resection) 




poor for the patient if not diagnosed early on during disease progression (Stenzl et 
al., 2012).  
 
 
The mechanism behind the action of cisplatin is based on its chloride atoms being 
displaced by water molecules, creating a hydrolysed product and potent electrophile 
which allows it to react with nitrogen donor atoms on nucleic acids. In the context of 
DNA, cisplatin bonds to purine residues causing several different variations of intra-
strand and inter-strand crosslinks. The most common variation is the 1,2-intra-strand 
d(GpG) adduct, accounting for 90% of all intra-strand adducts attributed to the action 
of cisplatin (Dasari & Tchounwou, 2014). Depending on exactly where the adducts 
are formed and the form in which they take, they can cause a significant change in 
the physical structure and shape of the DNA which is recognised by a variety of 
proteins involved in a number of different DNA repair or cell-cytotoxicity 
mechanisms. For example, since intra-strand crosslinks are the most common type 
of DNA lesion caused by cis-platin, they are primarily repaired by the NER DNA repair  
system, but cisplatin related damage can also recruit the TCR and HR repair systems 




and all of their related proteins (Basu & Krishnamurthy, 2010; Borst et al., 2008; 
Damsma et al., 2007).  
 
Cisplatin has historically been used to treat a wide variety of cancers for decades, but 
the more subtle interactions that it may have in cancers with specific mutational 
signatures could alter its effectiveness in treating the patient. These types of 
interactions couldn’t have previously been identified and studied before the drug 
was cemented as one of the most used in the world to treat many types of cancers, 
as the idea of mutational signatures wasn’t properly fleshed out and catalogued until 
2013 in Alexandrov et al’s seminal paper.  
 
In 2016 the idea of a relationship between the presence of mutational signatures and 
the use of certain chemotherapies was investigated in one study involving urothelial 
carcinomas. The study by Faltas et al collected urothelial carcinoma tumour samples 
from a number of patients before and after cisplatin-based chemotherapy, with a 
smaller subset of these matched to be from the same parental tumour (Faltas et al., 
2016). This gave an insight into the common genetic mutations that cancerous cells 
can go through as a result of the direct or indirect effects of such chemotherapy. 
Through whole exome sequencing they found that only 28.4% of mutations were 
shared between pre-chemotherapy and post-chemotherapy samples, suggesting 




of cisplatin chemotherapy to the patients which results in increased clonality after 
the fact without fully killing off the tumour cells. 
 
Upon further examination they found significant enrichment of C>G mutations at the 
characteristic TCW motifs (where W is either A or T) that the APOBEC3’s tend to act 
on in the post-chemotherapy tumour samples, as well as the presence of mutational 
signatures that looked remarkably similar to Sanger signatures 2 and 13 – highly 
indicative of APOBEC mutations (COSMIC, 2015). Further analysis of the favoured 
motif context of the mutations suggested that, specifically, A3A (and to a lesser 
extent A3B) could be the driving and dominant APOBEC3 culprit behind the majority 
of the mutations found in the post-chemotherapy tumours. Bearing in mind that only 
28.4% of the mutations were shared between pre-chemotherapy and post-
chemotherapy samples, these data suggest that the cisplatin-based treatment used 
here could be modifying or enhancing the effect that APOBEC3 enzymes have on the 
genome of the cancer cells, providing them with a higher amount of inter-clonal 
genetic diversity and therefore also the chance for surviving tumour cells to become 
resistant to the therapy and thus also become recurrent in the future. For example, 
it’s possible that the ssDNA generated during the repair of cisplatin-induced DNA 
breaks may act as a substrate for A3A, therefore making it more active than normal 
which would result in the A3A-specific mutational signatures seen in the post-
chemotherapy tumours. However, without further work it is impossible to say 




because of ongoing APOBEC activity during the chemotherapy, or whether the 
chemotherapy simply selected for minor sub-clones that existed before the 
treatment. 
 
Taken together, the extensive presence of A3A-induced mutations in post-
chemotherapy, metastatic urothelial carcinoma tumours shows that A3A could have 
the capability to not simply induce one time ‘fire and forget’ somatic mutations that 
might contribute to the formation of the initial cancer, but can could play a significant 
role in the evolution of advanced cancers. This can occur through the promotion of 
the clonal expansion of chemotherapy-resistant and possibly metastatic clones, 
perhaps due to an increased level of ssDNA made available to A3A as a result of the 
action of the cisplatin-based chemotherapy that is initially applied to treat the 







The culmination of existing work has highlighted the potential danger that the family 
of APOBEC enzymes, namely A3A, could pose to the continued effectiveness of 
platinum-based chemotherapy. Since Alexandrov et al’s paper detailing the discovery 
of mutational signatures and that two of these signatures can be attributed to one 
of the sub-families of the APOBEC enzymes, there have been a large number of 
studies that look into which member of this sub-family is the most likely to contribute 
to these mutational signatures and cause the most significant damage to the human 
genome. It is hard to ignore Cortez et al’s 2019 discovery that the Burns et al’s 2013 
seminal paper claiming that A3B is the main APOBEC culprit is based on data that can 
no longer be held as truly reliable (which was cited by at least 604 other papers at 
the time of writing). Cortez et al puts forward a convincing argument that it is indeed 
A3A that causes the most significant damage to the human genome, bringing 
together a wealth of new information to back this up. 
 
Studies such as that by Faltas et al provide a basis for the idea that cisplatin could be 
providing a novel route for bladder cancer cells into significantly higher levels of 
inter-clonality and thus also into a higher chance of recurring in the future than was 
ever thought to be the case. However, without a sample of bladder cancer cells with 
a full knockout of A3A (and ideally A3B) in order to A/B test and compare the 
timescales for development of resistance to cisplatin to a sample of WT bladder 




entirely possible that the cisplatin treatment is simply selecting for minor pre-existing 
subclones that have higher levels of APOBEC3 expression which existed before the 
rounds of cisplatin treatment, rather than actually contributing to some novel 
method of mutagenesis such as one that provides cells which have normal levels of 
APOBEC3 expression significantly more ssDNA substrate on which to act. If this is the 
case, then inhibition of APOBEC3 alongside cisplatin treatment would not be a viable 
method to prevent resistance to chemotherapy. It is also possible that both of these 
mechanisms may be at play, as has been shown to happen in EGFR-mutant non-
small-cell lung cancers to EGFR inhibitors, where drug-resistant cancer cells were 
shown to both pre-exist and evolve from drug-tolerant cells (Hata et al., 2016). 
 
Given the fact that at present there is no other drug that has similar levels of efficacy 
to cisplatin on such a wide variety of cancers (Dasari & Tchounwou, 2014), it is 
important to consider how best to enhance the activity and reduce the negative 
effects of the use of cisplatin in the interim period before a newer, more appropriate 
treatment option inevitably becomes available. Whilst still an endeavour, 
modulation of existing tried and tested treatment options with other known 
compounds will likely take less time and expense to research, licence and produce 
than the development of an entirely new treatment option. 
 
The aim of this project was to functionally test whether A3A plays a role in 




full knockout of A3A from a cell line has been published as of yet. Given the high 
relative levels of APOBEC mutations found in bladder cancer cells and the mounting 
evidence that APOBEC mutations are present in a large number of different cancers 
(albeit in varying levels), it would follow that bladder cancer would form a good base 
on which to begin testing if there is a relationship between the presence of the 
APOBEC signatures and prolonged effectiveness of cisplatin treatment.  
 
The possibility for this type of relationship was due to be studied by creating a 
number of qPCR verifiable clonal populations of wild-type BFTC-905 cells and their 
A3A KO equivalents using CRISPR-Cas9 and cell culture techniques such as single cell 
cloning, and then performing MTT cis-platin drug sensitivity assays over a number of 
weeks. This would allow for a comparison of the length of time it takes for the A3A 
KO cells to develop resistance to cisplatin compared to wild-type equivalents (if at 
all). The results of this study could give a use case for using APOBEC3 inhibitors 
alongside traditional chemotherapy treatment to enhance the recovery prospects for 
patients with cancers that have evidence of APOBEC mutational signatures. The idea 
to inhibit APOBEC3’s may be seen as detrimental due to their regular anti-viral 
activities within the cell, but it has been noted by others that there is likely a 
therapeutic window that exists for APOBEC3 inhibition, where “benefits will greatly 
outweigh the potential detriments of inhibiting only one component of the body’s 





I had taken over the work of a previous MSc-R student who had utilised CRISPR-Cas9 
and transfection techniques to successfully create a homozygous A3A knockout clone 
from the urothelial carcinoma cell line, BFTC-905 (Dooner, 2019). My plan was to 
focus on the homozygous A3A BFTC-905 knockout; creating, screening and verifying 
further clones from the pool of cells that the previous MSc-R student had produced. 
I would then have performed the MTT cisplatin drug sensitivity assays as mentioned 
above, followed by data analysis of the results. However, the extraordinary 
circumstances of COVID-19 and the resultant lockdown period led to me not having 
access to the lab just after I had developed and verified three parental wild-type 
BFTC-905 cell lines and two additional A3A KO BFTC-905 clones and performed 
preliminary growth tests, but before I could begin MTT drug sensitivity assays. My 
results and data are therefore limited compared to what should have been achieved 







Materials & Methods 
Tissue culture 
The human bladder cancer cell line BFTC-905 was maintained in IMDM with added L-
glutamine and 25mM HEPES supplemented with 10% FBS and 1% 
penicillin/streptomycin. Cells were cultured at 37°C and 5% CO2 in an incubator and 
grown to 80-90% confluency before being passaged. 
 
Cells were frozen down in 1mL aliquots in their normal growth medium and 
supplemented with 10% DMSO for longer term storage. They were initially stored in 
a -80°C freezer, before being moved into a nitrogen freezer after 2-5 days for 
indefinite storage. Revival of nitrogen-frozen cells was completed by rapid thawing 
in a 37°C water bath followed by dilution into 9mL of fresh warmed media and a spin 
down and resuspension in a further 5mL of IMDM, in order to remove any remaining 
DMSO. 
 
Once cells had been grown to a high enough volume and confluency, cell pellets were 
made at 500 RCF for 10 minutes and frozen in a -80°C freezer for later DNA extraction. 
 
Single cell cloning 
Cells were grown to 80-90% confluency before being serially diluted to a final 
concentration of 5 cells/mL. They were then plated into 96 well plates at 100µL per 




colonies to form. These plates were then screened for the presence of successful 
colonies under a microscope, and actively growing successful colonies were passaged 
into increasingly larger flasks after becoming confluent and given unique names 
before being frozen in growth medium containing 10% DMSO in liquid nitrogen as 
per the method above. 
 
DNA extraction 
One of two methods of DNA extraction were used depending on the available stock 
at the time: 
• A QIAGEN QIAamp DNA Mini Kit (Cat. No 51306) was used to extract DNA 
from cell pellets, completed according to the manufacture’s guidance. 
• A KAPA Express Extract kit (Cat No. KK7100) was used to extract DNA from 
cell pellets, according to the manufacturer’s guidance. This method was 
followed by an ethanol DNA precipitation to increase DNA purity. 
 
Extracted DNA was kept frozen at -20°C until required for use in PCR. 
 
Ethanol DNA precipitation 
0.1 vols of 3M Sodium acetate and 3 vols ice cold 100% ethanol was added to the 
extracted DNA (from the KAPA Express Extract Kit method above) and vortexed to 
mix thoroughly. This solution was precipitated at -20°C for 1 hour and then 




pellet was washed twice with 0.5mL ice cold 75% Ethanol, spinning at full speed at 
4°C for 10 mins each time. The ethanol was then removed, and the pellet spun for 10 
seconds at full speed to remove any trace amount of Ethanol. Finally, the pellet was 
air dried and resuspended in an appropriate volume of nuclease free water 
depending on the size of the pellet. 
 
RNA extraction 
A Monarch Total RNA Miniprep Kit (Cat. No T2010S) was used to extract RNA from 
cell pellets, completed according to the manufacturer’s guidance. Extracted RNA was 




A New England Biolabs LunaScript RT SuperMix Kit (Cat. No E3010) was used to 
synthesise cDNA from RNA for use in a two-step RT-qPCR workflow, completed 
according to the manufacture’s guidance. A concentration of 1,000ng/µL cDNA was 
initially achieved, then synthesised cDNA was diluted to a concentration of 5ng/µL 






PCR was completed using a KAPA HiFi HotStart ReadyMix PCR Kit (Kit Code: KK2601) 
according to the manufacturer’s instructions. Forward and reverse A3A primers with 
codes TRF497 and TRF498 were used (see Table 1 below). 
 
Agarose gel & PCR genotyping 
1% agarose gels were prepared with either 0.75g agarose to 75mL 1X TAE buffer for 
smaller running gels, or 1g agarose to 100mL 1X TAE buffer for larger running gels if 
more wells were needed. The 1% agarose mixture was microwave heated until the 
agarose had dissolved. When cooled down but still warm to the touch, ethidium 
bromide solution was added at 2.5µL ethidium bromide per 50mL agarose gel 
solution and the solution thoroughly mixed. This gel mixture was then poured into 
the appropriately sized gel cast with a gel comb and allowed to cool and set before 
the comb was removed. 
 
After 6X blue/purple loading dye was added and mixed with PCR products to make a 
final solution of 1X concentration, the set gel was placed into the gel tank and 
covered with 1X TAE buffer. PCR products mixed with loading dye were added to the 
gel wells alongside a Thermo 1Kb Plus DNA ladder (Cat. No 10787018) and 






Primer code Primer sequence Description 
TRF497 TGAGCTCACACCAGAACCAC A3A forward 
TRF498 TAGAGCCCAGAGAAGGTCCC A3A reverse 
Table 1 – A3A genotyping PCR primer codes and functions 
qPCR 
An Applied Biosystems PowerUp SYBR Green Master Mix (Cat. No A25741) was used 
in the two-step qPCR workflow, according to the manufacturer’s guidance, set up for 
a 10µL total reaction. Wells were set up in duplicate for each sample and no-template 
controls were also set up in duplicate for each sample in order to identify any 
contamination. The following primers were used: 
 
Primer code Primer sequence Description 
TRF566 GAGAAGGGACAAGCACATGG A3A forward 
TRF567 TGGATCCATCAAGTGTCTGG A3A reverse 
TRF568 GACCCTTTGGTCCTTCGAC A3B forward 
TRF569 GCACAGCCCCAGGAGAAG A3B reverse 
TRF589 CCCATGACTCCCATGACC TBP forward 
TRF590 TTTACAACCAAGATTCACTGTGG TBP reverse 
TRF596 GTCATCCATGACAACTTTGGTA GAPDH forward 
TRF597 GGATGATGTTCTGGAGAGC GAPDH reverse 





FuGENE HD transfection reagent (Cat No. E2311) was used to transfect clonal pre-
flippase (cells in which the PGK-Puro-delta TK selection cassette was still present in 
intron 1 of A3A (figure 7)) A3A KO cell lines with a Flippase-GFP plasmid and an empty 
GFP plasmid as a negative control according to the manufacturer’s guidance. The 
concentration of the Flippase-GFP plasmid was determined using a UV spectrometer 
(Nanodrop) and had a concentration of 677.3ng/µL. 26µg of DNA was needed for the 
transfection according to the manufacturer’s guidance, therefore 26,000ng/677.3ng 
= 38.38µL of Flippase-GFP plasmid was added to 1202.62µL of optimem medium to 
make a total of 1241µL transfection solution (as required by the manufacturers’ 
guidance, indicated for the three T25 flasks). Transfections were later checked for 






Figure 7 -This figure illustrates the A3A targeting vector used by the previous student in this study. The vector 
contains a puromycin resistance gene and an HSV-TK gene which together form the selection cassette. The 
puromycin resistance gene allows for positive selection after inserting the vector, and the HSV-TK gene confers 
ganciclovir sensitivity which allows for negative selection after the vector has been removed by flippase (from the 
Flippase-GFP plasmids) at the FRT sites, marked as triangles. The red section in intron 1 of the vector represents 
a stop codon which, after inserted into the WT allele, knocks out A3A giving A3A KO cells. The estimated length of 
the wild type A3A allele is 3797bp, the targeted allele is 5508bp and the final targeted allele with the selection 
cassette removed is 2980bp. The difference in lengths allows for genotyping of cell populations to ensure effective 
targeting at each stage. 
Successfully transfected cells were selected for using ganciclovir to remove 
unsuccessfully transfected cells still containing the selection cassette and therefore 
also the HSV-TK ganciclovir susceptibility conferring gene. Transfected C9, C28 and 
KO 2.1 cells were plated in 10mL of media with 5µL of 20µM ganciclovir at a low 





For each cell line, five 96 well plates were set up, each with 6 rows with a length of 
10 wells of cell concentrations of: 
• 500 cells per well 
• 1,500 cells per well 
• 2,000 cells per well 
• 3,000 cells per well 
• 4,000 cells per well 
• 5,000 cells per well 
 
Surrounding these rows were wells filled with IMDM media to minimise evaporation 
of media within the central wells containing the cells. Each of the five plates for every 
cell line were grouped and allocated to be read on a plate reader on each day out of 
a consecutive period of five days. This allows growth data to be obtained every day 
for five days for every concentration of cell listed above, for all cell lines. Every day, 
MTT was added to every row in each plate for each cell line allocated to the following 
day and left to incubate overnight. The next day SDS was added to that days set of 
plates and read to measure growth rates. MTT was then added to the following days 





PCR & genotyping 
PCR and subsequent genotyping were carried out on the parental WT, A3A KO pre-
Flippase and A3A KO post-Flippase + selection cell lines in order to verify each 
populations’ A3A status (Figure 8). This is possible due to the different molecular 
weights of the WT A3A allele (3797bp), the targeted A3A allele with the selection 
cassette inserted (5508bp) and the final targeted A3A allele with the selection 
cassette removed (2980bp) (Figure 7).  
 
The A3A KO pre-Flippase KO 2.1 cell line’s band is the same molecular weight as the 
band for the post-Flippase and selection of the same cell line as, unknowingly at the 




time, the pre-Flippase KO 2.1 cell line had already had its selection cassette removed 
by the previous MSc-R student. Ideally a repeat of this gel would have been 
completed to improve its clarity and reduce the ambiguity of the image as this was a 
first attempt, however this was not possible due to lockdown restrictions. 
 
Growth curves (MTT assays) 
Cell viability (MTT) assays were performed over 5 days to determine the optimum 
plating densities for drug sensitivity assays and to generate growth curves for each 
WT and A3A KO clone. This would reveal the optimum starting concentration for each 
of the cell lines taken forward to the MTT drug sensitivity assays in the future. This 
method also allows for the comparison of the growth characteristics of the cells not 
only to each other over time, but also to each other after the removal of the selection 
cassette and the addition of any drug. Please note that due to the COVID-19 
lockdown, I was only able to generate data for two A3A KO clones and none of the 
parental (WT) clones. 
 
The resultant data showed similar growth rates for all cell lines, growing largely 































C28 Post Selection Growth Curve
5000 cells/well 4000 cells/well 3000 cells/well
















KO 2.1 Post Selection Growth Curves
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FuGENE HD plasmid transfection 
After growing an extensive stock of A3A KO SSC's, adding to the single existing A3A 
KO clone that the previous master’s student had generated, the selection cassette 
had to be removed in order to mitigate any interference between the selection 
cassette and the surrounding genes, notably A3B. 
 
The selection cassette also contains a ganciclovir susceptibility gene (Herpes Simplex 
Virus Thymidine Kinase - HSV-TK) which confers ganciclovir sensitivity. By using 
flippase to remove the selection cassette and therefore also the HSV-TK gene, it 
becomes possible to select for the cells that have had the cassette successfully 
removed by plating the resultant cell populations out with ganciclovir. The required 
cells that have had the cassette and the HSV-TK removed will survive the ganciclovir 
treatment, whilst the cells that have had an unsuccessful transfection die off upon 
inoculation with ganciclovir. A GFP tag was included within the plasmid in order to 
visualise successful transfection and transcription of the GFP and therefore also the 
flippase within the cells. 
 
Transfections were successful with GFP appearing within the nuclei of cells when 
viewed under a Luma-Scope, indicating high efficiency of transfection and expression 











Validation of A3A KO clones 
Following the single cell cloning and Flippase transfection protocols, it was necessary 
to check that the resultant populations of cells were in fact truly A3A KO or WT cells. 
To do this, qPCR was utilised with APOBEC3A primers to check that there was no 
expression of the A3A gene in the A3A KO cell lines and normal levels of A3A 
expression in the WT cell lines. A3B primers where also used to check that knocking 
out A3A did not interfere with expression of A3B, along with primers for the 
housekeeping genes TBP and GAPDH to compare amplification data with (Table 2). 
Housekeeping genes are recognised as essential cell maintenance genes with 
relatively stable expression levels across sample or treatments groups. This means 
that expression data for other genes can be compared to the stably expressed 
housekeeping genes in order to normalise for any differences in input cDNA quantity 
(Turabelidze et al., 2010). 
 
qPCR melt curve data clearly shows a strong peak for the parental cell lines that 
indicates the presence of A3A (Figure 14), and much weaker and non-specific peaks 
for the A3A KO cells, indicating a lack of A3A (Figure 15). These non-specific peaks 
are likely due to contamination as none are close to the melting temperature of A3A 
seen in the parental cell melt curves. The variation in expression of A3A and A3B seen 
in the parental cells could be due to the cells being in different stages of the cell cycle 





The raw qPCR amplification data also shows that the three parental cells lines carried 
forward all display similar levels of amplification of A3A relative to each other, as 
expected. Both of the suspected A3A knockouts show amplification only at very late 
cycles if at all, consistent with a total lack of A3A mRNA in these clones (Supplemental 
data – figures 16, 17, 18 & 19). qPCR data was converted into copy number data using 
standard curves and was then normalised to the TBP housekeeping gene. The 
resultant data shows a drastic reduction in the levels of A3A copy numbers seen in 
the A3A KO C28 and KO 2.1 cell lines compared to the parental cell lines (Figure 12). 
Importantly, the levels of A3B expression were similar in the parental and A3A KO 
cell lines (Figure 13), meaning that the A3A knockout process could not have 
significantly affected the expression of A3B in the C28 and KO 2.1 cell lines. 
 
Please note that the final A3A knockout that was created and due to be carried 
forward, C9, was not able to be qPCR verified due to COVID-19 and not having access 
to the lab. Biological repeats should also have been completed in an attempt to 
remove or reduce the non-specific peaks seen in the data and to increase its 






Figure 12 - Chart showing the decrease in copy numbers of A3A seen in the C28 & KO 2.1 cell lines compared to 





Figure 13 - Chart showing similar levels of copy numbers of A3B in the C28 & KO 2.1 cell lines compared to the 
parental cell lines on a linear scale. The similar levels of copy numbers seen here would suggest that the process 








Figure 14 - qPCR melt curve for A3A primers in parental cells (P2, P3 & P6) 
 
 






Unfortunately, due to the COVID-19 outbreak I had to leave the university labs and 
was unable to complete MTT drug sensitivity assays on the qPCR-verified A3A KO and 
WT cell lines that I had cultured during my time at the lab, and to initiate the long-
term drug-sensitisation protocol on these clones. When looking at the whole project, 
this is likely to have been the most important part and I am very disappointed to not 
have been able to complete it. It would likely have given me a large dataset to have 
worked with and analysed, potentially giving meaningful insights into how A3A may 
interact with bladder cancer cells, perhaps giving evidence for a viable use case for 
the use of A3A inhibitors alongside traditional cisplatin chemotherapy as a way to 
prolong the usefulness of the drug and preventing, or at the least delaying, the onset 
of cisplatin resistance within the bladder cancer cells. 
 
However, I can still elaborate on what I would have expected to happen given the 
other ongoing research in the area. Therefore, this discussion will include 
information both on the experiments that I completed myself and what they mean, 
as well as what I think is most likely to have happened in the final stages of my project 
had I been able to complete it based on some relevant information on other studies 






I conducted 5-day growth curves on all but one of the cell lines carried forward (P2, 
P3, P6, C28 & KO 2.1). This was done so that when I would have started the MTT 
cisplatin sensitivity assays I would have had a good idea as to what the optimum 
starting concentrations for each of the cell lines would have been. I was looking for 
the highest possible startling cell concentration that didn’t level off up to the 5th day 
of growth. This would mean that, come the ‘real’ MTT assay, the cells would have the 
best possible chance of establishing themselves in the wells of the 96 well plate whilst 
not slowing down growth before the last day of the experiment. 
 
The results show that in most of the cell lines growth doesn’t begin to level off at all, 
even up to the final day and highest cell concentration I tested (5,000 cells/well). 
However, as it is important that all cell starting concentrations would have been the 
same in the MTT drug sensitivity assay, I would have the chosen 2,000 cells/well 
starting concentration, as it is the only concentration tested that did not show any 
levelling off at any point in any of the cell lines (Figures 9 & 10).  
 
Validation of cells using qPCR 
The amplification levels corresponding to the A3A primers were very clear in the 
parental cells and virtually non-existent in the A3A KO cells. (Figures 14 & 15). This 
data confirms that all preceding processes leading up to this point to knock out the 




which the amplification levels of the A3A primers in the A3A KO cells become 
significant are above 30, with some as high as ~37 (supplemental data, figure 16). 
According to a paper detailing qPCR guidelines, it can be considered safe to disregard 
qPCR results with Cq values that are as high as this, instead classifying them as ‘noise’ 
(Bustin et al., 2009). All parental cell lines and all knockout cell lines show broadly 
similar levels of A3B amplification, indicating that knocking out A3A did not affect the 
expression of A3B and meaning the A3A KO cells can be reliably compared to wild 
type cells when undertaking drug sensitivity assays. 
 
Predictions 
MTT drug sensitivity assays 
As talked about in the ‘Accelerating mutation formation’ section of this thesis, 
studies have shown that there is an extensive presence of the APOBEC3 mutational 
signature in a large number of different cancers and particularly in bladder cancer. 
More recent studies have shown that the exact favoured motif context of the 
mutations would suggest that it is A3A, and not the long-thought A3B, which is the 
main contributor to these mutational signatures. Finally, it has also been shown that 
the commonly used cisplatin chemotherapy used to treat patients with certain types 
of bladder cancer (amongst many other types of cancer) may be interacting with 
APOBEC3’s to enhance their mutational effects on cancer genomes, causing them to 
mutate at an even greater extent than normal. This could contribute to the ‘just right’ 




cisplatin and A3A could be causing levels of mutation in the cancer genome that are 
just high enough to evade selection pressures (such as the cisplatin itself), but not so 
high that the cancer cells begin to fail to propagate information properly down to 
their daughter cells. 
 
Having taken everything together, I would hypothesise that the A3A KO cells that 
have been developed so far would show both lower levels of survival and a longer 
period of time to become resistant to cisplatin in the MTT assays compared to the 
WT parental cells. However, both the WT parental and A3A KO cells would eventually 
become resistant to the cisplatin over time if a long enough MTT assay were to be 
run. This is because although the evidence does point towards A3A as being a potent 
mutator, it is far from being the only endogenous mutagen that could cause such an 










To summarise, I was able to create two more clonal populations of the BFTC-905 A3A 
KO cells (in addition to the single clonal population that was created by the previous 
student), and three separate clonal populations of the parental WT BFTC-905 cells 
using SSC techniques. I was also able to successfully prove using qPCR that the 
transfection protocols were successful and that there were cells present in each A3A 
KO population that had had their selection cassettes removed and A3A gene knocked 
out. 
 
Due to the exceptional circumstances surrounding COVID-19 and the lockdown 
period, I was unable complete the original plan of using these cells in MTT drug 
sensitivity experiments. The large bulk of work involving the creation of the BFTC-
905 A3A KO cells using CRISPR-Cas9 (completed by the previous student) and time-
consuming culture of multiple clonal cell populations of both the A3A KO and WT 
BFTC-905 cells has now been completed. The important MTT assay results for this 
work are now just around the corner and could give an idea as to whether or not A3A 
is playing a significant role in the formation of cisplatin resistance in these BFTC-905 
bladder cancer cells. The data from these experiments could give a reason to further 
investigate the effects of inhibition of A3A on the formation of drug resistance in 
other cell lines as well as further elucidate the specific drug interactions that A3A 





To date, there have been no other studies that have looked into the effects of A3A 
using full knockout rather than knockdown or inhibition experimentation methods. 
Fully knocking out A3A from the cell line and performing A/B test MTT assay 
experiments will give a much more solid idea as to the function of A3A in cancer cells 
– in many other studies referenced in this thesis that look into the APOBEC3’s, it is 
impossible to tell for certain whether the results they are seeing are truly to do with 
the action of A3A (or the lack thereof) or secondary effects that arise from the 












Figure 16 - A3A qPCR amplification plot for the C28 and KO 2.1 A3A knockout cell lines 






Figure 18 - A3B qPCR amplification plot for the parental P2, P3 & P6 cell lines 
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